Aurinia 制药

最新新闻

• 评级变动
  RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Hold Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)
  TipRanks · 2026/3/31
• 评级变动
  Leerink Partners Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2025/7/2
• 评级变动
  TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11
  \u5e02\u573a\u8d44\u8baf · 2025/8/1
• Bloom Burton Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 评级变动
  RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Cuts Target Price to $8
  \u5e02\u573a\u8d44\u8baf · 2025/2/28
• 评级变动
  Jefferies Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21
  \u5e02\u573a\u8d44\u8baf · 2025/11/7
• 评级变动
  TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $17
  \u5e02\u573a\u8d44\u8baf · 2025/11/5
• Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, Vs. FactSet Est of $0.20
  MT Newswires · 2026/5/7
• 评级变动
  Leerink Partners Downgrades Aurinia Pharmaceuticals(AUPH.US) to Hold Rating, Raises Target Price to $16
  \u5e02\u573a\u8d44\u8baf · 2025/12/3
• Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q2 Revenue $83.2M, Vs. FactSet Est of $80.4M
  MT Newswires · 2026/8/6
• 评级变动
  H.C. Wainwright Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• 评级变动
  TR | OpenAI - 4o Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $13
  \u5e02\u573a\u8d44\u8baf · 2025/8/6
• 评级变动
  RBC Capital Downgrades Aurinia Pharmaceuticals(AUPH.US) to Hold Rating, Raises Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2025/11/5
• 评级变动
  Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Hold Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/3/31
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Aurinia Pharmaceuticals (AUPH) and RegenXBio (RGNX)
  TipRanks · 2025/5/13
• Aurinia Pharmaceuticals(AUPH.US) 10% Shareholder Buys US$12.46 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/6/3
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)
  TipRanks · 2026/3/2
• 评级变动
  H.C. Wainwright Initiates Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Announces Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2025/7/30

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。